Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia
Gecacitinib Combined With Luspatercept in Patients With Myelofibrosis and Anemia: A Single-center, Prospective, Single-arm Study
This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Bing Han
- Telefonnummer: 01065295027
- E-Mail: hanbing_li@sina.com.cn
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 18 years or older.
- Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria.
- Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment.
- No previous treatment with a Janus kinase inhibitor.
- Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, immunosuppressants, corticosteroids, and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment.
- Splenomegaly, with the spleen palpable 5 cm below the left costal margin.
- Hemoglobin below 100 g/L, with or without red blood cell transfusion dependence.
- Platelet count of at least 75 × 10^9/L.
- Absolute neutrophil count of at least 1.0 × 10^9/L.
- Peripheral blood blasts of 10% or less.
- Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy of more than 6 months.
- Ability to independently provide written informed consent.
Exclusion Criteria:
-
Clinically significant anemia associated with iron, vitamin B12, or folate deficiency; autoimmune or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia.
-
Active infection.
-
A history of malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ.
-
Significant hepatic or renal dysfunction, or dysfunction of another major organ.
-
Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:
- Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L.
- Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment.
- Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
-
Previous splenectomy.
-
Previous treatment with any transforming growth factor-beta ligand inhibitor.
-
Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child.
-
Suspected hypersensitivity to gecacitinib, luspatercept, or drugs of the same class.
-
Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Gecacitinib + Luspatercept
gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks |
Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be based primarily on platelet counts and absolute neutrophil counts. Gecacitinib will be interrupted if the platelet count falls below 50 × 10^9/L and may be resumed when the platelet count recovers to at least 50 × 10^9/L. Luspatercept will be administered by subcutaneous injection at an initial dose of 1.0 mg/kg every 3 weeks. The dose may be adjusted according to blood counts, up to a maximum of 1.75 mg/kg. Treatment may be interrupted if the predose hemoglobin level is at least 120 g/L or if hemoglobin increases rapidly by more than 20 g/L. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Achieving an Anemia Response
Zeitfenster: 24 week
|
Anemia response is defined as conversion from red blood cell transfusion dependence at baseline to transfusion independence, or an increase in hemoglobin of at least 20 g/L in participants who do not require red blood cell transfusions and have a baseline hemoglobin level of 100 g/L or lower. |
24 week
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
Zeitfenster: 24 week
|
Percentage of participants achieving an increase in mean hemoglobin of at least 1.0 g/dL from baseline for at least 12 consecutive weeks without red blood cell transfusions. |
24 week
|
|
Time to Anemia Response
Zeitfenster: week 24
|
Time from the first dose of study treatment to the first documented anemia response. |
week 24
|
|
Duration of Anemia Response
Zeitfenster: week 24
|
The longest continuous duration of anemia response among participants who achieve an anemia response. |
week 24
|
|
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
Zeitfenster: week 24
|
Changes from baseline in the amount and frequency of red blood cell transfusions during study treatment. |
week 24
|
|
Change From Baseline in Hemoglobin
Zeitfenster: weeks 4, 8, 12, 16, 20, and 24
|
Change in hemoglobin concentration, measured in g/L, from baseline at scheduled treatment-period visits. |
weeks 4, 8, 12, 16, 20, and 24
|
|
SVR35
Zeitfenster: week 12 and 24
|
Percentage of participants achieving a reduction in spleen volume of at least 35% from baseline. |
week 12 and 24
|
|
DoMSR
Zeitfenster: week 24
|
Time from the first documented reduction in spleen volume of more than 35% from baseline to the first subsequent assessment showing a reduction of less than 35% from baseline. |
week 24
|
|
MPN-SAF TSS
Zeitfenster: weeks 4, 8, 12, 16, 20, and 24
|
Percentage of participants achieving a reduction of at least 50% from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS). |
weeks 4, 8, 12, 16, 20, and 24
|
|
Reduction in Fatigue Score
Zeitfenster: week 24
|
Percentage of participants achieving a reduction of at least 50% from baseline in fatigue symptom score. |
week 24
|
|
Adverse Events
Zeitfenster: From the first dose through 28 days after the last dose.
|
Incidence and severity of adverse events, including events that develop or worsen during treatment and events occurring after treatment that are considered related to the study drugs by the investigator. Serious adverse events and adverse events leading to treatment interruption or discontinuation will also be recorded. |
From the first dose through 28 days after the last dose.
|
|
PFS
Zeitfenster: 12 month
|
Time from the first dose of study treatment to disease progression or death from any cause, whichever occurs first. |
12 month
|
|
OS
Zeitfenster: 12 month
|
Time from the first dose of study treatment to death from any cause. |
12 month
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- K11529
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .